Lift Global Ventures plc to join AQSE Growth Market. The Company’s investment strategy is to operate as an enterprise company seeking acquisition or investment opportunities within the financial media and technology industries. Within these broad industries, areas of focus may include: Financial news websites and other forms of “new media”, Investment research providers, Financial PR, IR, design and marketing agencies, Production studios and visual content providers and Technology platforms which facilitate capital raising and/or lending. Mkt Cap and Capital to be raised TBC, expected 29 April.
Shellraise plc, to join AQSE Growth Market. The Company will focus on identifying investment opportunities in companies operating in the viticulture sector which require funding to increase output. Mkt Cap and Capital to be raised TBC, expected later in April.
7digital 0.32p £8.7m (7DIG.L)
The specialist in B2B end-to-end digital music solutions, has signed a new two-year contract worth at least £1m with a pan-Asian consumer services company. The new customer will be using several unique services provided by 7digital’s music-as-a-service platform to deliver an app-based music streaming service to enhance its engagement with its customers. The Company will provide access to its global catalogue, full license compliance management and curation via the 7digital Playlisting Tool. Paul Langworthy, CEO of 7digital, said: “This is a major, multi-year contract for 7digital that further enhances our visibility over our forecast revenues for the next two years. It is an important endorsement of our offering having been awarded by a multinational corporation and after a competitive tender. This win also reflects how brands are increasingly utilising digital music solutions to engage with their customers. We’re pleased to see our pipeline continue to translate to signed contracts and we look forward to updating the market on further progress.”
Botswana Diamonds 1.1p £9.3m (BOD.L)
The diamond explorer, announced the results of a conceptual open pit mine optimisation evaluation on the River Blow on its Thorny River property in South Africa. An analysis of the River Blow and its extension indicates potential open pit options. Assuming mid-range diamond values of $170/ct, mid-range mining costs, a discount rate of 10%, a recovered grade of 40cpht and 1.7M tons of kimberlite mined indicates that a mine is likely to be commercial. The results exclude any additional resources from adjacent targets which will be drilled in the coming months.
Cadence Minerals 17.13p £29.5m (KDNC.L)
Further to the announcement made on the 7 April 2022, Cadence Minerals announced that DEV Mineração S.A’s has completed the sale and shipment of Iron Ore from the Amapa Iron Ore Project. DEV has shipped and sold the fourth batch of iron ore from the stockpiles. The loading of the 48,492 wet tonnes of iron ore sinter fines (approx. 58% Fe) at Companhia Docas de Santana was completed on the 23 April. Iron Ore 62% Fe, CFR China at US$150 per tonne (22/04/2022). Approximately 1.2 Mt of iron ore is currently stockpiled in DEV’s wholly-owned port.
Ixico 38p £18.3m (IXI.L)
The medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides a trading update ahead of its interim results for the six months ended 31 March 2022. Revenues expected to be £3.9m for six months to 31 March 2022 (H1 2021: £4.9m); Contracted order book of £12.6m as at 31 March 2022 (H1 2021: £19.0m); Strong cash balance of £5.8m (H1 2021: £7.0m), debt free, and operating cash generative; Positive earnings before interest, tax, depreciation and amortisation to 31 March 2022 (H1 2021: £0.9m); Across the first six months of the year, the Company has performed in line with its expectations and the Board continues to expect to deliver a stronger second six months to meet market expectations for FY22.
K3 Capital 245p £180m (K3C.L)
The multi-disciplinary and complementary professional services group advising UK SMEs has announced the appointment of former ManpowerGroup Executive Vice President, Ian Symes, as its new Group Managing Director. Ian joins K3 from ManpowerGroup, where he was Executive Vice President and global leader of the Right Management brand, a HR solutions business employing more than 900 staff across 35 countries with revenues of more than $200m. Ian joins K3 with extensive international experience having led businesses across Europe and North America. Ian will primarily be supporting the Group’s CEO, John Rigby, in leading the operations of K3’s expanding portfolio of businesses. John commented: “Ian brings an incredible wealth of leadership experience in B2B services, growing businesses across different sectors and geographies. We are excited that he joins K3 Capital Group as we accelerate our business, increasing market share and expanding into new services and sectors.” Ian commented on his appointment: “I am very excited to be joining such a forward thinking and rapidly growing company, and I am looking forward to working alongside the existing management teams to help drive the Group to the next level.”
MusicMagpie 50p £53.9m (MMAG.L)
The re-commerce business in the UK and US specialising in refurbished consumer technology, has entered into a contract to sell consumer electronic products on Back Market, the online marketplace dedicated to refurbished devices. The launch of musicMagpie’s products will occur on the Back Market UK marketplace by the end of this month and on the Back Market US marketplace in mid-May 2022. In addition to mobile phones, the agreement includes tech categories such as games consoles, tablets, wearables and MacBooks. The launch adds an additional sales channel for musicMagpie’s products and will supplement existing sales through its own websites as well as Amazon and eBay.
Polarean Imaging 56p £119m (POLX.L)
The medical imaging technology company, with an investigational drug device combination product using hyperpolarised 129 Xenon gas to enhance magnetic resonance imaging in pulmonary medicine, announces it has received an additional research unit order for a Xenon Polariser 9820. The system will be installed in the Center for Pulmonary Imaging Research at the Cincinnati Children’s Medical Center (CCHMC). The Company holds a Small Business Innovation Research grant with the Cincinnati Children’s Center, awarded by the National Heart, Lung and Blood Institute in April 2017. CCHMC is a non-profit academic medical center, which is distinguished and globally renowned for paediatric teaching and research, and is one of the Company’s longest key clinical collaborators. A key focus of the collaboration is to lead the field of paediatric pulmonary imaging through advanced imaging techniques and multi-nuclear capabilities, including hyperpolarised 129 Xenon gas.
Premier African Minerals 0.32p £62.1m (PREM.L)
Premier African Minerals Limited has signed a binding Joint Venture Agreement with Li3 Resources Inc. whereby Li3 Resources will acquire a 50% interest in Premier’s hard-rock lithium assets located in the Mutare Greenstone Belt in Zimbabwe. Premier acquired these claims in June 2020 (see RNS 10 June 2020). The assets are held by Premier’s wholly-owned subsidiary LicoMex Private Limited. The Li3 Project holds a number of prospective claim blocks in the Mutare Greenstone Belt, an area prospective for lithium and gold. This JV Agreement facilitates exploration activities that are funded independently of Premier’s Zulu Lithium Private Limited operations. Li3 Resources has until 31 December 2022 to acquire the 50% interest in the Li3 Project by spending US$250k in further exploration works.
Union Jack Oil 28.75p £32.4m (UJO.L)
The UK focused onshore hydrocarbon production, development and exploration company, announced that material landmark net revenues of US$5m have been achieved from the Wressle hydrocarbon development, located within licences PEDL180 and PEDL182 in North Lincolnshire on the western margin of the Humber Basin. Union Jack holds a 40% economic interest in this producing hydrocarbon development. Landmark US$5m revenues generated to Union Jack since re-commencement of production during August 2021. Well continues to produce under natural flow with zero water cut. Site upgrades ongoing. As at 22 April 2022, the Company’s cash balances and short term receivables stand at in-excess of £7.05m. Net revenues of £2.4m registered to date during 2022, already comfortably exceed 2021 year-end unaudited revenues of in-excess of £1.8m. The Company is covered for all operational and all contracted or planned CAPEX costs, including any budgeted drilling activities. Debt free. Company solicitors progressing legal work on Capital Reduction exercise to enable the Company to execute share buy-back programme or dividend payment.
Zoo Digital 119p £105.1m (ZOO.L)
The provider of end-to-end, cloud-based localisation and media services to the global entertainment industry, today provides a pre-close trading update for the financial year ending 31 March 2022 in advance of full year results expected to be announced on 6 July 2022. Following the announcement on 22 March 2022, where revenue was forecast to be at least $65m and EBITDA at least $6.5m, the Group today further upgrades its expectations for the year ended 31 March 2022. Revenue for the full year is now expected to be approximately $70m (FY21: $39.5m), a significant acceleration of organic growth over the prior year of 78%. EBITDA (adjusted for share-based payments) is also expected to be materially ahead of the previously upgraded expectations at approximately $8m, an increase of approximately 78% on the prior year (FY21: $4.5m). Net cash on 31 March 2022 was $5.4m (FY21: $2.9m), which reflects strong cash generation despite significant investment to expand capability and underpin future revenue growth. The Company intends to provide a further update on its outlook for the FY23 financial year with its full year results on 6 July 2022.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
